🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being described as a "huge turning point" in the fight against increasingly resistant strains of the infection, according to health experts.

A Global Challenge

Gonorrhoea infections are increasing worldwide, with estimates suggesting over 82 million infections annually. Particularly high rates are reported in the African continent and nations within the WHO's designated area, which spans from China and Mongolia to New Zealand. In England, cases have hit a historical peak, while figures across Europe in 2023 were significantly elevated compared to those in 2014.

“The approval of new treatments for gonorrhoea is an significant and necessary step in the reality of growing infection rates, escalating drug resistance and the very limited therapeutic options at this time.”

Public health authorities are particularly alarmed about the increase in drug-resistant strains. The global health body has classified it as a "critical concern". Recent surveillance found that the effectiveness of standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Drugs Secure Authorization

One new antibiotic, also known as Nuzolvence, was approved by the American regulatory agency in mid-December for combating gonorrhoea. This infection can lead to serious health problems, including infertility. Experts believe that targeted use of this new drug will help hinder the spread of drug resistance.

Gepotidacin, created by the drugmaker GSK, also received approval in close succession. This drug, which is additionally indicated for UTIs, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin stemmed from a innovative non-profit model for medication research. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to see it through.

“This milestone marks a significant shift in the management of multidrug-resistant gonorrhoea, which up to this point has been staying ahead of medical innovation.”

Testing Data and Global Access

As per data detailed in a prominent scientific publication, zoliflodacin successfully treated more than 90% of cases of the STI. This puts it on an similar efficacy with the typical regimen, which involves an injection and a pill. The study included over 900 participants from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, the non-profit has the ability to make available and distribute the drug in many developing nations.

Doctors directly involved have voiced positive views. The availability of a single-dose, oral treatment of this kind is seen as a "revolutionary step" for public health efforts. This is deemed essential to reduce the burden of the disease for patients and to prevent the spread of untreatable gonorrhoea globally.